Literature DB >> 26318603

Distinct spatiotemporal patterns for disease duration and stage in Parkinson's disease.

Simon Badoud1,2,3, Nicolas Nicastro1,3, Valentina Garibotto3,4, Pierre R Burkhard1,3, Sven Haller5,6,7,8.   

Abstract

PURPOSE: To assess correlations between the degree of dopaminergic depletion measured using single-photon emission computed tomography (SPECT) and different clinical parameters of disease progression in Parkinson's disease (PD).
METHODS: This retrospective study included 970 consecutive patients undergoing (123)I-ioflupane SPECT scans in our institution between 2003 and 2013, from which we selected a study population of 411 patients according to their clinical diagnosis: 301 patients with PD (69.4 ± 11.0 years, of age, 163 men) and 110 patients with nondegenerative conditions included as controls (72.7 ± 8.0 years of age, 55 men). Comprehensive and operator-independent data analysis included spatial normalization into standard space, estimation of the mean uptake values in the striatum (caudate nucleus + putamen) and voxel-wise correlation between SPECT signal intensity and disease stage as well as disease duration in order to investigate the spatiotemporal pattern of the dopaminergic nigrostriatal degeneration. To compensate for potential interactions between disease stage and disease duration, one parameter was used as nonexplanatory coregressor for the other.
RESULTS: Increasing disease stage was associated with an exponential decrease in (123)I-ioflupane uptake (R(2) = 0.1501) particularly in the head of the ipsilateral caudate nucleus (p < 0.0001), whereas increasing disease duration was associated with a linear decrease in (123)I-ioflupane uptake (p < 0.0001; R(2) = 0.1532) particularly in the contralateral anterior putamen (p < 0.0001).
CONCLUSION: We observed two distinct spatiotemporal patterns of posterior to anterior dopaminergic depletion associated with disease stage and disease duration in patients with PD. The developed operator-independent reference database of 411 (123)I-ioflupane SPECT scans can be used for clinical and research applications.

Entities:  

Keywords:  123I-ioflupane SPECT; Disease duration; Disease stage; Parkinson’s disease; Voxel-wise analysis

Mesh:

Substances:

Year:  2015        PMID: 26318603     DOI: 10.1007/s00259-015-3176-5

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  35 in total

1.  Improved optimization for the robust and accurate linear registration and motion correction of brain images.

Authors:  Mark Jenkinson; Peter Bannister; Michael Brady; Stephen Smith
Journal:  Neuroimage       Date:  2002-10       Impact factor: 6.556

2.  Use of a single [123I]-FP-CIT SPECT to predict the severity of clinical symptoms of Parkinson disease.

Authors:  Ruth Djaldetti; Therese A Treves; Ilan Ziv; Eldad Melamed; Yair Lampl; Mordechai Lorberboym
Journal:  Neurol Sci       Date:  2009-06-05       Impact factor: 3.307

3.  Practical benefit of [123I]FP-CIT SPET in the demonstration of the dopaminergic deficit in Parkinson's disease.

Authors:  J Booij; G Tissingh; A Winogrodzka; G J Boer; J C Stoof; E C Wolters; E A van Royen
Journal:  Eur J Nucl Med       Date:  1997-01

4.  Threshold-free cluster enhancement: addressing problems of smoothing, threshold dependence and localisation in cluster inference.

Authors:  Stephen M Smith; Thomas E Nichols
Journal:  Neuroimage       Date:  2008-04-11       Impact factor: 6.556

5.  Parkinsonism: onset, progression and mortality.

Authors:  M M Hoehn; M D Yahr
Journal:  Neurology       Date:  1967-05       Impact factor: 9.910

6.  Correlation of Parkinson's disease severity and duration with 123I-FP-CIT SPECT striatal uptake.

Authors:  H T Benamer; J Patterson; D J Wyper; D M Hadley; G J Macphee; D G Grosset
Journal:  Mov Disord       Date:  2000-07       Impact factor: 10.338

7.  Measurement of the dopaminergic degeneration in Parkinson's disease with [123I] beta-CIT and SPECT. Correlation with clinical findings and comparison with multiple system atrophy and progressive supranuclear palsy.

Authors:  T Brücke; S Asenbaum; W Pirker; S Djamshidian; S Wenger; C Wöber; C Müller; I Podreka
Journal:  J Neural Transm Suppl       Date:  1997

8.  SPECT imaging of dopamine and serotonin transporters with [123I]beta-CIT: pharmacological characterization of brain uptake in nonhuman primates.

Authors:  M Laruelle; R M Baldwin; R T Malison; Y Zea-Ponce; S S Zoghbi; M S al-Tikriti; E H Sybirska; R C Zimmermann; G Wisniewski; J L Neumeyer
Journal:  Synapse       Date:  1993-04       Impact factor: 2.562

9.  MR signal abnormalities at 1.5 T in Alzheimer's dementia and normal aging.

Authors:  F Fazekas; J B Chawluk; A Alavi; H I Hurtig; R A Zimmerman
Journal:  AJR Am J Roentgenol       Date:  1987-08       Impact factor: 3.959

10.  [Elaboration of the SPM template for the standardization of SPECT images with 123I-Ioflupane].

Authors:  F J García-Gómez; D García-Solís; F J Luis-Simón; V A Marín-Oyaga; F Carrillo; P Mir; R J Vázquez-Albertino
Journal:  Rev Esp Med Nucl Imagen Mol       Date:  2013-04-06       Impact factor: 1.359

View more
  3 in total

1.  Neuroprotection of Granulocyte Colony-Stimulating Factor for Early Stage Parkinson's Disease.

Authors:  Sheng-Tzung Tsai; Sung-Chao Chu; Shu-Hsin Liu; Cheng-Yoong Pang; Ting-Wen Hou; Shinn-Zong Lin; Shin-Yuan Chen
Journal:  Cell Transplant       Date:  2016-12-07       Impact factor: 4.064

2.  Discriminating among degenerative parkinsonisms using advanced (123)I-ioflupane SPECT analyses.

Authors:  Simon Badoud; Dimitri Van De Ville; Nicolas Nicastro; Valentina Garibotto; Pierre R Burkhard; Sven Haller
Journal:  Neuroimage Clin       Date:  2016-07-05       Impact factor: 4.881

Review 3.  Optimizing Parkinson's disease diagnosis: the role of a dual nuclear imaging algorithm.

Authors:  J William Langston; Jesse C Wiley; Michele Tagliati
Journal:  NPJ Parkinsons Dis       Date:  2018-02-23
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.